Search

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen's TEZSPIRE (tezepelumab) demonstrated a statistically [...]

Alexion, AstraZeneca Rare Disease and Merck, known as MSD outside of the United States and Canada, announced positive topline results from the phase 3 KOMET trial, which is the largest, [...]

Positive high-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre phase III trial in adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), showed [...]

Hutchmed (HCM) announced high-level results from the SAVANNAH Phase II trial that showed Tagrisso plus Orpathys demonstrated a high, clinically meaningful and durable objective response rate, or ORR, for patients [...]

Arcus Biosciences (RCUS) announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan, Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients [...]

2024 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - Drug Development. According [...]

AIM ImmunoTech (AIM) announced positive preliminary data from the Phase 1b/2 study evaluating the combination of AIM's Ampligen and AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of [...]

Updated results from the HIMALAYA Phase III trial showed AstraZeneca's Imfinzi plus Imjudo demonstrated a sustained, clinically meaningful overall survival, or OS, benefit at five years for patients with unresectable [...]

Updated results from the HIMALAYA Phase III trial showed AstraZeneca's Imfinzi plus Imjudo demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma [...]

Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca's Calquence in combination with venetoclax, with or without obinutuzumab, demonstrated a [...]

High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group, showed Imfinzi did not achieve statistical significance for the primary endpoint of disease-free survival, [...]

The CAPItello-290 Phase 3 trial for Truqap in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer, or TNBC, did not meet the dual primary [...]

Positive results from the ECHO phase III trial showed AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) [...]

Results from the ECHO Phase III trial showed AstraZeneca's CALQUENCE in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and showed a [...]

Results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable, Stage III epidermal growth [...]

Results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to [...]

Byline: Nandita Vijayasimha, Bengaluru India's is now a key hub for lifesciences Global Capability Centers (GCCs). This according to multinational majors like Amgen, GSK, Eli Lily, Bayer, Mylan, AstraZeneca among [...]

High-level overall survival (OS) results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favoured datopotamab deruxtecan (Dato-DXd) compared to docetaxel [...]

High-level overall survival, or OS, results from the TROPION-Lung01 Phase III trial, which previously met the dual primary endpoint of progression-free survival, or PFS, numerically favoured datopotamab deruxtecan, or Dato-DXd, [...]

Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's Calquence in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically [...]

Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy [...]

Positive high-level results of the ADRIATIC phase III trial showed AstraZeneca's Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) [...]

High-level results of the ADRIATIC Phase III trial showed AstraZeneca's Imfinzi demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival [...]

Results of the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in [...]

Results from the FLAURA2 phase III trial showed AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in [...]

Results from the FLAURA2 Phase 3 trial showed AstraZeneca's Tagrisso with the addition of chemotherapy provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients [...]

Latest analysis of the results from the DUO-E phase III trial showed Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) demonstrated an improvement [...]

AstraZeneca announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with chronic [...]